Search the Newsreel

Biodesix Inc (BDSX) major holder Jack W. Schuler buys 15,000 shares

Jack W. Schuler, a major holder and emeritus director of Biodesix Inc. (BDSX), indirectly purchased 15,000 shares of common stock on August 12, 2026. The shares were bought at a weighted average price of $24.4661 per share through the Jack W. Schuler Living Trust, …

Biodesix Insider Bought Shares Worth $366,992, According to a Recent SEC Filing

An insider at Biodesix (BDSX) recently purchased shares valued at $366,992, as disclosed in a recent SEC filing. This transaction was published on August 13, 2026, at 05:40 pm EDT, according to MT Newswires. Biodesix specializes in diagnostic solutions, particularly for lung cancer testing …

Biodesix, Inc. (NASDAQ:BDSX) Given Consensus Rating of "Moderate Buy" by Brokerages

Biodesix, Inc. (NASDAQ:BDSX) has received a "Moderate Buy" consensus rating from five brokerages, with an average 12-month price target of $31.33. This comes as the company exceeded quarterly expectations, reporting revenues of $26.86 million and a lower-than-expected adjusted loss per share. Insider activity also …

Biodesix Sees Nodify Growth, Reaffirms Revenue Outlook at Canaccord Conference

Biodesix reaffirmed its full-year revenue guidance of $108 million to $114 million, representing approximately 25% year-over-year growth at the midpoint, and expects to achieve positive adjusted EBITDA on a run-rate basis soon. The company highlighted growth in its Nodify CDT test, driven by commercial …

Insider Buying: Biodesix (NASDAQ:BDSX) Director Purchases 13,900 Shares

Biodesix (NASDAQ:BDSX) Director Jack Schuler recently purchased 13,900 shares of the company's stock for over $337,000, increasing his direct stake by 2.71%. The company reported better-than-expected quarterly revenue and EPS, although it remains unprofitable. Analysts maintain a "Moderate Buy" rating for Biodesix with an …

Biodesix director Jack Schuler buys $665,940 in company stock

Biodesix Inc. (NASDAQ:BDSX) Director Jack W. Schuler recently acquired 27,600 shares of company stock for approximately $665,940 through two transactions on August 10 and 11, 2026. These purchases occurred as the stock trades near its 52-week high after a 257% year-to-date surge, despite InvestingPro …

Biodesix (BDSX) major holder Jack W. Schuler adds shares via trusts

Jack W. Schuler, a major shareholder and emeritus director of Biodesix Inc. (BDSX), has increased his holdings through open-market purchases made via the Jack W. Schuler Living Trust. Over two days, August 10 and August 11, 2026, Schuler acquired a total of 27,600 shares …

HC Wainwright Forecasts Biodesix's Q3 Earnings (NASDAQ:BDSX)

HC Wainwright has updated its Q3 2026 EPS estimates for Biodesix (NASDAQ:BDSX), lowering it to a loss of $0.75 per share, while maintaining a "Buy" rating and a $27 price target. This follows Biodesix's recent Q2 earnings report where the company surpassed analyst expectations, …

BDSX Maintained by Canaccord Genuity -- Price Target Raised to $35

Canaccord Genuity has maintained a 'Buy' rating for Biodesix (BDSX) and increased its price target from $27.00 to $35.00, indicating strong confidence in the company's future. While analysts are optimistic about Biodesix's growth, particularly in medical diagnostics, the stock is considered modestly overvalued according …

Canaccord Genuity Group Issues Positive Forecast for Biodesix (NASDAQ:BDSX) Stock Price

Canaccord Genuity Group has increased its price target for Biodesix (NASDAQ:BDSX) to $35 from $27, maintaining a "buy" rating and implying a significant upside of 48.94%. This positive forecast aligns with a "Moderate Buy" consensus rating from other analysts, supported by the company's recent …

Canaccord raises Biodesix stock price target on strong test volume

Canaccord has increased its price target for Biodesix Inc. (NASDAQ:BDSX) to $35 from $27, maintaining a Buy rating, due to higher revenue projections for 2026 and beyond. This adjustment follows Biodesix's strong second-quarter 2026 results, which surpassed estimates, driven by increased Nodify test volume …

Earnings Update: Here's Why Analysts Just Lifted Their Biodesix, Inc. (NASDAQ:BDSX) Price Target To US$32.67

Biodesix, Inc. (NASDAQ:BDSX) recently released its quarterly results, showing better-than-expected revenues of US$27m and smaller statutory losses of US$0.71 per share. Following these results, analysts have updated their forecasts for 2026, predicting revenues of US$111.5m and reduced losses per share. This positive outlook has …

Biodesix Inc (BDSX) Stock News Today

Biodesix (BDSX) Stock Pullback Puts Focus On Losses Despite Stronger Margins

Biodesix (BDSX) stock saw a nearly 3% pullback despite reporting a narrowed net loss of US$7.3m and a strong gross margin of 82% in Q2 2026. While revenue increased by 34% year-over-year, the market focused on the company's continued losses, raising questions about whether …

Biodesix boosts sales, trims loss as diagnostics firm pushes toward profitability

Biodesix Inc. (Nasdaq: BDSX) reported improved top and bottom lines in the second quarter, indicating progress towards profitability. The life-sciences company, which specializes in lung diagnostic tools, has shown consistent efforts to boost sales and reduce losses. This financial improvement positions Biodesix on a …

Biodesix, Inc. Stock 12‑Month Price Target Raised to $32.67, Implies 43% Upside

Biodesix, Inc. (BDSX) has seen its average 12-month price target increased by analysts from $30.83 to $32.67, suggesting a potential 43% upside based on the Aug. 5 closing price. The consensus rating from 7 analysts remains a "Buy," with all seven recommending the stock.

Biodesix, Inc. Reports Impairment Loss on Intangible Assets for the Second Quarter Ended June 30, 2026

Biodesix, Inc. announced an impairment loss on intangible assets for the second quarter ended June 30, 2026. The reported impairment loss was $12,000, a decrease from $26,000 in the same period last year. This information was released on August 5, 2026, as part of …

Biodesix, Inc. (BDSX) Reports Q2 Loss, Beats Revenue Estimates

Biodesix, Inc. (BDSX) reported a Q2 loss of $0.71 per share, which beat the Zacks Consensus Estimate of a $0.86 loss, marking a 17.44% surprise. The company's revenues for the quarter reached $26.86 million, exceeding estimates by 2.92% and showing growth from $20.02 million …

BIODESIX ($BDSX) Releases Q2 2026 Earnings

Biodesix Inc (NASDAQ:BDSX) is scheduled to release its Q2 2026 earnings on August 5, 2026, with analysts expecting revenue of $26.03 million and earnings of -$0.91 per share. GuruFocus indicates a 6.22% upside based on its GF Value, while analysts have an average target …

Biodesix Diagnostic Testing Revenue Climbs 42% as Tests Reach 20,900

Biodesix reported strong Q2 2026 results, with total revenue increasing 34% to $26.9 million, driven by a 42% rise in Diagnostic Testing revenue. Test volumes grew by 38% to 20,900, contributing to an 82% gross margin. Despite a net loss of $7.3 million, the …

Biodesix (Nasdaq: BDSX) grows Q2 2026 revenue 34% to $26.9M

Biodesix (Nasdaq: BDSX) reported a 34% year-over-year revenue increase in Q2 2026, reaching $26.9 million, driven by a 42% rise in Diagnostic Testing revenue. Despite this growth and an improved gross margin of 82%, the company still reported a net loss of $7.3 million …

BIODESIX Inc Q2 2026: Revenue $26.86M, EPS $(0.71) — 10-Q Summary

BIODESIX Inc (BDSX) reported its Q2 2026 results, showing a 34% year-over-year revenue increase to $26.86 million and a narrowed net loss of $7.27 million, or $(0.71) per share, compared to $(1.56) in Q2 2025. The company's diagnostic testing revenue grew by 42%, driven …

Biodesix (NASDAQ: BDSX) lifts lung test revenue and raises $23.9M equity

Biodesix (NASDAQ:BDSX) Announces Earnings Results

Biodesix to Participate in Canaccord Genuity’s 46th Annual Growth Conference

Biodesix, Inc. announced that its leadership team will participate in Canaccord Genuity's 46th Annual Growth Conference. They will present in a fireside chat and hold in-person investor meetings from August 11-12, 2026. The fireside chat is scheduled for August 12, 2026, at 3:30 PM …

Biodesix leadership's Aug. 12 fireside chat will be webcast live

Biodesix (Nasdaq: BDSX) announced that its leadership team will participate in Canaccord Genuity’s 46th Annual Growth Conference from August 11-12, 2026. The team will host a fireside chat on August 12, 2026, at 3:30 PM ET, which will be webcast live and available for …

Biodesix Inc expected to post a loss of 90 cents a share - Earnings Preview

Biodesix Inc is projected to report a loss of 90 cents per share. This information comes from a Refinitiv earnings preview. The full article is available on TradingView, which aggregates news from various sources including Reuters.

Biodesix Inc (BDSX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Biodesix Inc (BDSX), noting its current price momentum score and suggesting it's suitable for range-bound swing trading with resistance at 24.41 and support at 18.59. It details various technical indicators like MACD, RSI, and moving averages (MA5 …

Biodesix (BDSX) to Post Earnings on Wednesday

Biodesix (BDSX) is scheduled to release its Q2 2026 earnings after market close on Wednesday, August 5th. Analysts anticipate a loss of $0.86 per share on revenue of approximately $26.03 million. In the previous quarter, the company surpassed estimates by reporting a loss of …

Biodesix, Inc. Revenue Breakdown – NASDAQ:BDSX

This document provides a revenue breakdown for Biodesix, Inc. (NASDAQ: BDSX), accessible through TradingView. It offers an overview of the company's financial information, including statements, statistics, dividends, earnings, and segment performance by source and country. The information is sourced from ICE Data Services, FactSet, …

Biodesix Market Sentiment

This article analyzes market sentiment for Biodesix (BDSX) based on analyst consensus, short interest, options flow, and insider activity. It highlights a "Buy" consensus from analysts with varied price targets and details recent analyst actions including upgrades, downgrades, and initiations. The article also mentions …

Biodesix Inc (BDSX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Biodesix Inc (BDSX) Income Statement

This article provides the quarterly and annual income statements for Biodesix Inc. (BDSX), detailing financial performance metrics such as total revenue, operating expenses, and net income from Q3 2020 through Q1 2026. It also includes frequently asked questions about understanding and analyzing the company's …